CERTARA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.57 USD | +1.66% |
|
+4.02% | -5.80% |
| Apr. 16 | Certara Launches Cloud Platform to Unify Scientific Software Solutions | MT |
| Apr. 16 | Certara, Inc. Launches Cloud Platform to Further Unify Its End-To-End Scientific Software Platform | CI |
Presentation Operator MessageOperator (Operator)Hello, and thank you for standing by Welcome t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.
Sector
Software
Calendar
2024-05-06
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
16.57
USD
Average target price
19.74
USD
Spread / Average Target
+19.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.80% | 2.65B | |
| +8.05% | 3,020B | |
| +5.58% | 82.93B | |
| +3.69% | 76.85B | |
| -14.62% | 53.04B | |
| +31.16% | 50.15B | |
| -24.56% | 46.55B | |
| +17.75% | 41.41B | |
| +55.21% | 35.63B | |
| -10.24% | 24.64B |
- Stock Market
- Equities
- CERT Stock
- News Certara, Inc.
- Transcript : Certara, Inc., Q4 2023 Earnings Call, Feb 29, 2024
